News Updates

Jazz Pharmaceuticals unveiled results of its Phase II/III trial for Rylaze, or asparaginase erwinia chrysanthemi (recombinant)-rywn delivered intramuscularly in acute lymphoblastic leukemia patients or those with lymphoblastic lymphoma who developed a hypersensitivity to E. coli-derived L-asparaginase. Data were presented at the annual meeting of the American Society of Clinical Oncology and detailed the treatment's positive benefit-risk profile when administered using a dosing schedule of three days in a week, with its safety profile seemingly consistent with other asparaginases. Healio (free registration) (6/12)